Emerging targeted therapies in myelofibrosis. - Wikidata - wikimedia - TriplyDB

Emerging targeted therapies in myelofibrosis.

Emerging targeted therapies in myelofibrosis.

http://www.wikidata.org/entity/Q38025160

about

Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside.Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage.

P2860

Q33407110-F5B0C162-104D-4D12-9BE3-DBD037DAFD1C Q50890627-3803521D-CCBC-4C26-A829-64CD61B525A9

P2860

Emerging targeted therapies in myelofibrosis.

http://www.wikidata.org/entity/Q38025160

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Emerging targeted therapies in myelofibrosis.

@en

type

label

Emerging targeted therapies in myelofibrosis.

@en

prefLabel

Emerging targeted therapies in myelofibrosis.

@en

P1433

Q38025160-53FC67B0-2E9E-4743-8D10-8D3402E1EF95

P1476

Q38025160-BC870F29-47C2-4572-BD7F-60E4EDE505FE

P2093

Q38025160-A935377F-67C2-4580-8C86-0AACFD457354

P2860

Q38025160-02373978-DC4F-4C70-89C5-B4B00C629B3E

Q38025160-05EF8D4D-C4BA-434E-AA1C-84569604255D

Q38025160-0906E7F7-3846-4704-B3EF-919B119528F1

Q38025160-09119A23-4063-43FE-AE80-655C1BCFF1FE

Q38025160-0EA4151E-FC42-42C6-929A-A26895D65D19

Q38025160-0EF2265C-6A5F-46B8-AE1D-7959F4DB3FC9

Q38025160-11C55ECC-118A-48BF-822F-18BA8EB4AAC6

Q38025160-13032309-0F28-4FE6-B8CA-DB9B6E814F40

Q38025160-17D71598-93B2-4250-AF6D-710BDA58D374

Q38025160-192F8C39-6725-40DC-BC31-C44A95E4C7EA

P304

Q38025160-18B99C89-375A-46C2-81A0-05D5552AE297

P31

Q38025160-B3A4357C-C51E-4F03-8B96-92ED3426A2CD

P356

Q38025160-B5CA854A-6C5B-40A0-8813-ED4C5EE855C3

P433

Q38025160-9A71F977-D522-4255-9847-290C23C731D6

P478

Q38025160-E4B16463-D0FB-42A5-BDAB-2A45D7B0A1CD

P577

Q38025160-E0162366-92F3-42F5-8E4E-A64DEEAC6647

P698

Q38025160-8C63D240-8B5E-481E-BE1A-98C7C23B4426

P356

P1433

Expert Review of Hematology

P1476

Emerging targeted therapies in myelofibrosis.

@en

P2093

Giovanni Barosi

http://www.w3.org/2001/XMLSchema#string

P2860

Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1

JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin

Janus kinases in immune cell signaling

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis

Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation

P304

313-324

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/EHM.12.17

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22780211

http://www.w3.org/2001/XMLSchema#string